In a previous study, the researchers showed that PSA scores can impact both doctor and patient behavior, leading to biopsy ...

A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment ...

Mayo Clinic researchers developed MedEduChat, an AI-powered EHR tool that delivers personalized prostate cancer education ...

A polygenic risk score was able to detect a high proportion of clinically significant prostate cancer. Cancer would not have been detected in 71.8% of patients with the use of PSA or MRI screening.

The US FDA has granted De Novo marketing authorization for ArteraAI Prostate (Artera, Los Altos, California), a novel artificial intelligence (AI)-powered risk-stratification tool for patients with ...

FDA-authorized AI tools have the potential to help patients with prostate cancer get clearer answers instead of waiting weeks for genomic test results. FDA-authorized artificial intelligence (AI) ...

The NHS is embarking on a trial that could cut prostate cancer diagnosis times from weeks to a single day. The initiative uses artificial intelligence to analyze MRI scans, potentially transforming ...

A new study is set to investigate how AI could significantly improve doctors’ decisions regarding prostate cancer treatment. While diagnostic methods for the disease have become safer and more precise ...

SYRACUSE, N.Y.--(BUSINESS WIRE)--Associated Medical Professionals (A.M.P.) announced today the availability of the ArteraAI Prostate Test, an AI-powered risk stratification tool to help personalize ...

This undated microscope image provided by the National Institutes of Health shows cancer cells with the cell nuclei stained red. The U.S. Food and Drug Administration approved the use of Paige ...